Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
LATEST NEWS
AACE EXCLUSIVE: Interview with Dr. Aaron Vinik
- Video Excerpt: The Hesitancy to Use New Drugs
- Video Excerpt: T1 and SGLT-2s
- Full Interview Transcript
The dust has settled from the ADA scientific sessions in New Orleans and we have had time to look at what we learned about SGLT-2 Inhibitors. There were at least 40 posters on how they work and what they can do, but there was not a whole lot about clinical use. The information from the recent AACE meeting had more of a clinical leaning. Our publisher, Steve Freed, had a chance to spend time with one of our Advisory Board members, Aaron Vinik, to get his clinical opinions on why some prescribers are sometimes hesitant to start a patient on an SGLT-2 inhibitor while others are ready to use them on all patients, including type 1s.
Dave Joffe
Editor-in-chief
LATEST NEWS
New study indicates canagliflozin superior to glimepiride in lowering A1C.
AACE EXCLUSIVE: Interview with Dr. Aaron Vinik
Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 5 of this Exclusive Interview, Dr. Vinik explains the caution on the part of doctors to use the latest SGLT-2 medications despite apparent benefits.
Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 6 of this Exclusive Interview, Steve asks Dr. Vinik his opinion on type 1 and SGLT-2s.
In this exclusive interview, Dr. Vinik shares his views on what matters in studying bariatric surgery outcomes, and why weight loss and effect on diabetes are not the key questions for him.